Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Florida Gulf Coast have busted the brackets of would-be basketball prognosticators.
Here at The Motley Fool, we decided to stick with what we know, trading our basketball picks in for stock picks. We formed our own Sweet 16 filled with the top Big Pharma and Big Biotech stocks in a winner-take-all tournament determined by the collective intelligence of our CAPS community.
This matchup is a heavyweight bout between Celgene and Biogen Idec. Watch and find out which stock gets eliminated and which will advance to the next round.
David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavid. Max Macaluso, Ph.D. and The Motley Fool also have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Juno Therapeutics Stock Is Soaring Today
The pharmaceutical industry's long-anticipated consolidation of CAR-T biotech companies may be starting.
Will 2018 Be Celgene Corporation's Best Year Yet?
The answer is yes. And no.
Here's What Celgene's Management Just Said About Its Future
An optimistic outlook could spark interest in the large-cap biotech's shares.